B
Brent N. Rexer
Researcher at Vanderbilt University
Publications - 23
Citations - 1019
Brent N. Rexer is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Breast cancer & Lapatinib. The author has an hindex of 12, co-authored 19 publications receiving 886 citations. Previous affiliations of Brent N. Rexer include The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
TL;DR: Early clinical data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of respective HER2+ and ER+ breast cancers resistant to standard therapies.
Journal ArticleDOI
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Aleix Prat,Tomás Pascual,Carmine De Angelis,Carolina Gutierrez,Antonio Llombart-Cussac,Tao Wang,Javier Cortes,Brent N. Rexer,Laia Paré,Andres Forero,Antonio C. Wolff,Serafin Morales,Barbara Adamo,Fara Brasó-Maristany,Maria Vidal,Jamunarani Veeraraghavan,Ian E. Krop,Patricia Galván,Anne Pavlick,Begoña Bermejo,Miguel Izquierdo,Vanessa Rodrik-Outmezguine,Jorge S. Reis-Filho,Susan G. Hilsenbeck,Mafalda Oliveira,MV Dieci,MV Dieci,Gaia Griguolo,Gaia Griguolo,Roberta Fasani,Paolo Nuciforo,Joel S. Parker,Pierfranco Conte,Rachel Schiff,Valentina Guarneri,C. Kent Osborne,Mothaffar F. Rimawi +36 more
TL;DR: Combining HER2-E subtype and ERBB2 mRNA into single assay identifies tumors with high responsiveness to Her2-targeted therapy and could help de-escalate chemotherapy in ∼40% of patients withher2-positive breast cancer.
Journal ArticleDOI
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
TL;DR: This work adds to a growing body of cell lines in culture that have provided insights into mechanisms of resistance that can be interrogated in primary tumors in patients, and discusses strategies to identify and overcome resistance to TKIs.
Journal Article
Retinoic acid biosynthesis by normal human breast epithelium is via aldehyde dehydrogenase 6, absent in MCF-7 cells.
TL;DR: In this article, aldehyde dehydrogenase 6 (ALDH6) was identified as the enzyme responsible for the loss of RA synthesis ability in cancer cells and the relationship of this process to malignant transformation.
Journal ArticleDOI
Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells.
Rafael Mira-y-Lopez,Wen Li Zheng,Yuvarani S. Kuppumbatti,Brent N. Rexer,Yongkui Jing,David E. Ong +5 more
TL;DR: It is hypothesize that retinol bioactivity is impaired in breast cancer cells that cannot synthesize RA and preliminary support of this hypothesis is found thatretinol (0.5–2 μM) inhibited MCF‐10F but not T47D orMCF‐7 cell growth.